Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
2020-03-23
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
2019-09-04
ISS&ISE Reports Have Been Submitted to the FDA
2017-12-27
Zensun Successfully Raised Approximately ¥504 million (US$76 million)
2017-12-20
Zensun’s Listing Ceremony Held In Beijing For The Initial Listing Of Shares
2017-06-13
地址：上海市浦东张江高科技园区居里路68号沪ICP备06030993号-2
